AstraZeneca’s initial application for a lupus injection has been turned down by the FDA. The company is now working closely with the U.S. regulator to proceed with an updated application. They have mentioned that a decision on the updated application is expected to be made in the first half of 2026. This setback highlights the rigorous regulatory process in the pharmaceutical industry, emphasizing the importance of meeting all requirements and standards set by the FDA to bring new treatments to market.

<The Wall Street Journal 뉴스 본문 전체읽기>